Angiographic follow-up and clinical experience with the flexible tantalum cordis stent

Watson, Paul S.; Ponde, Chandrashekhar K.; Aroney, Constantine N.; Cameron, James N.; Cannon, Adam; Dooris, Mark; Garrahy, P.; McEniery, Paul T.; Bett, J. H. N.

doi:10.1002/(sici)1097-0304(199802)43:2<168::aid-ccd12>3.0.co;2-k

Cited by 8 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, there were very few adverse clinical events. These findings compare favorably with those of randomized trials of stent implantation in highly selected patient and lesion groups and registry data [2][3][4][5][6][7][8][9][10][11]. The use of stents during coronary interventional procedures has increased dramatically over the 6 years since the Benestent and STRESS trials demonstrated reduced restenosis rates with stent deployment compared with angioplasty for focal de novo coronary artery lesions [2,3].…”

Section: Discussionsupporting

confidence: 53%

“…This has been particularly apparent over the last 6 years, exemplified by our unit where stents were used in only 13% of procedures in 1992 compared to over 80% in 1998. A major reason for their increased usage is the availability of newer designs that have overcome the limitations of earlier generation stents [5][6][7][8][9][10][11]. This article describes our initial clinical experience obtained in a consecutive series of patients with a full spectrum of coronary lesions undergoing V-Flex Plus stent deployment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preliminary experience with the V-Flex Plus coronary stent: Immediate and one-month clinical outcome

Rhydwen

Webster

Ruygrok

et al. 1999

Cathet. Cardiovasc. Intervent.

View full text Add to dashboard Cite

Procedural and 1‐month outcome data following implantation of the V‐Flex Plus stent in our first 54 consecutive patients (35 male; mean age, 62 years) are described. Sixty‐four stents were implanted for 60 mainly complex lesions; 48% were left anterior descending; 20%, circumflex; 27%, right coronary artery; and 5%, saphenous vein graft. The indication for stenting was elective in half of the patients and for a suboptimal result or as a bailout procedure in the other half. The stents were deployed at a mean of 12 atm (range, 6–18) and postdilated to a mean of 15 atm (range, 8–20). Pre‐ and postdilatation balloon sizes were 2.96 ± 0.57 mm and 3.16 ± 0.34 mm, respectively. The procedural success rate was 98%. There were no deaths or Q‐wave myocardial infarctions. One patient suffered a non–Q‐wave myocardial infarction and another developed a femoral false aneurysm. At 1‐month follow‐up, there were no additional events, in particular no revascularization procedures. Eighty‐nine percent of patients were free of angina. Implantation of the V‐Flex Plus stent is safe and effective with an excellent early success rate comparable to that of published randomized trials and registries of carefully selected patients. Cathet. Cardiovasc. Intervent. 47:504–508, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Preliminary experience with the V-Flex Plus coronary stent: Immediate and one-month clinical outcome

Rhydwen

Webster

Ruygrok

et al. 1999

Cathet. Cardiovasc. Intervent.

View full text Add to dashboard Cite

show abstract

“…Studies [3], [8], [9] have shown that Ta metal is appropriate for osteogenesis in animal implantation tests, and in vivo studies have proven it suitable for cell adhesion, proliferation, and differentiation [10]–[12]. Ta has also been used to fabricate stents and artificial heart valves for cardiac and vascular devices because of its high corrosion resistance and radio-opacity properties [13], [14]. The biocompatibility of Ta have been identified and widely applied to various biomedical materials and devices.…”

Section: Introductionmentioning

confidence: 99%

Biological Characteristics of the MG-63 Human Osteosarcoma Cells on Composite Tantalum Carbide/Amorphous Carbon Films

et al. 2014

View full text Add to dashboard Cite

Tantalum (Ta) is a promising metal for biomedical implants or implant coating for orthopedic and dental applications because of its excellent corrosion resistance, fracture toughness, and biocompatibility. This study synthesizes biocompatible tantalum carbide (TaC) and TaC/amorphous carbon (a-C) coatings with different carbon contents by using a twin-gun magnetron sputtering system to improve their biological properties and explore potential surgical implant or device applications. The carbon content in the deposited coatings was regulated by controlling the magnetron power ratio of the pure graphite and Ta cathodes. The deposited TaC and TaC/a-C coatings exhibited better cell viability of human osteosarcoma cell line MG-63 than the uncoated Ti and Ta-coated samples. Inverted optical and confocal imaging was used to demonstrate the cell adhesion, distribution, and proliferation of each sample at different time points during the whole culture period. The results show that the TaC/a-C coating, which contained two metastable phases (TaC and a-C), was more biocompatible with MG-63 cells compared to the pure Ta coating. This suggests that the TaC/a-C coatings exhibit a better biocompatible performance for MG-63 cells, and they may improve implant osseointegration in clinics.

show abstract

“…(Int J Cardiovasc Intervent 2000; 3: 215-225) are available from newer stents, but thrombotic occlusion remains reported in the same range. [5][6][7] The in uence of stent design remains more controversial. Stent-associated restenosis is still a clinical problem, depending on technical and clinical variables; notably the presence of diabetes, 8 small vessel diameter or long lesions 9,10 are associated with a higher incidence.…”

Section: Introductionmentioning

confidence: 99%

“…In vitro and in vivo studies have consistently demonstrated decreased brinogen uptake and activation and adhesion of platelets on PC-coated materials. [7][8][9] However, to demonstrate reduction of thrombogenicity in a clinical setting would require an impractically large number of patients. Several animal studies have shown no sign of in ammatory reaction or other adverse vessel wall response to PC-coated stents, but the coating alone has not been shown to reduce intimal hyperplasia.…”

Section: Introductionmentioning

confidence: 99%

Multicenter evaluation of the phosphorylcholinecoated biodivYsio stent in short de novo coronary lesions: The SOPHOS study

et al. 2000

International Journal of Cardiovascular Interventions

View full text Add to dashboard Cite

AIMS: The BiodivYsio trade mark stent (Biocompatibles Ltd, Farnham, UK) is coated with a phosphorylcholine (PC)-containing copolymer to confer biocompatibility. The SOPHOS (Study Of PHosphorylcholine coating On Stents) study was designed to assess the safety and efficacy of this novel coronary stent and by indirect comparison to indicate equivalence with other formal stent studies. METHODS AND RESULTS: Patients with angina and a single short (#x2A7F;12 mm) de novo lesion in a native coronary artery of >/=2.75 mm diameter were included. A total of 425 patients were allocated in 24 centers. Clinical data were collected at one-, six- and nine-month follow-up. Angiography was performed before and after the stent implantation. In addition, in the first 200 patients (SOPHOS A) angiography was routinely performed at six months. The following 225 patients (SOPHOS B) were merely followed up clinically. The primary end-point of the study, the six-month MACE-rate (MACE = Major Adverse Cardiac Events) was 13.4% (two cardiac death; five Q-wave/nine non-Q-wave myocardial infarctions (MI); nine CABG and 32 target lesion revascularization (TLR), which is similar to the calculated 15% MACE-rate in comparable reference studies. Secondary end-points included among others restenosis at six months in the SOPHOS A population. The target vessel diameter was 2.98 +/- 0.48 mm. Minimal lumen diameter pre/post procedure and at follow-up was 1.00 +/- 0.32, 2.69 +/- 0.37, 1.91 +/- 0.71 mm, respectively. The binary restenosis rate (>/=50% diameter stenosis at follow-up) was 17.7%. CONCLUSION: The coronary BiodivYsio stent is safe and effective as a primary device for the treatment of native coronary artery lesions in patients with stable or unstable angina pectoris. Clinical and angiographic results are in the statistical range of equivalence with comparable studies with other current stents.

show abstract

Angiographic follow-up and clinical experience with the flexible tantalum cordis stent

Cited by 8 publications

References 18 publications

Preliminary experience with the V-Flex Plus coronary stent: Immediate and one-month clinical outcome

Preliminary experience with the V-Flex Plus coronary stent: Immediate and one-month clinical outcome

Biological Characteristics of the MG-63 Human Osteosarcoma Cells on Composite Tantalum Carbide/Amorphous Carbon Films

Multicenter evaluation of the phosphorylcholinecoated biodivYsio stent in short de novo coronary lesions: The SOPHOS study

Contact Info

Product

Resources

About